Supplemental Figure 2 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

Alexandre Bazinet,Sai Prasad Desikan,Ziyi Li,Juan Jose Rodriguez-Sevilla,Sangeetha Venugopal, Samuel Urrutia,Guillermo Montalban-Bravo,Koji Sasaki,Kelly S. Chien,Danielle Hammond,Rashmi Kanagal-Shamanna,Irene Ganan-Gomez,Tapan M. Kadia,Gautam Borthakur,Courtney D. DiNardo,Naval G. Daver,Elias J. Jabbour,Farhad Ravandi,Hagop Kantarjian,Guillermo Garcia-Manero

crossref（2024）

引用 0|浏览5

暂无评分

摘要

Supplemental Figure 2: Overall survival and event-free survival in HMA-naïve patients with HR-MDS treated with HMA plus venetoclax versus a contemporary cohort treated with HMA monotherapy.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要